Do you want to read an article? Please log in or register.
Encouraging Results with First-In-Class Targeted Therapy in Essential Thrombocythemia
Myeloproliferative Neoplasms (MPNs)
EHA/ICML 2025
Related content
Head and Neck Cancer
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
Exp Hematol Oncol
Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N
doi: 10.1186/s40164-025-00703-x
Lung, Respiratory and Thoracic Cancer
Treatment sequences in BRAF-V600-mutated non-small cell lung cancer: First-line targeted therapy versus first-line (chemo-) immunotherapy
J Thorac Oncol
Wiesweg M, Alaffas A, Rasokat A, Saalfeld FC, Rost M, Assmann C, Herster F, Hilbrandt M, Griesinger F, Kron A, Roeper J, Glanemann F, Kropf-Sanchen C, Reck M, Kulhavy J, Stenzinger A, Wolf J, Sebastian M, Schuler M, Wermke M, Frost N, Kopp HG, Christopoulos P, Scheffler M
doi: 10.1016/j.jtho.2025.04.016
Gastrointestinal Cancer
Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer
Eur J Cancer
Weiss L, Stintzing S, Stahler A, Benedikt Westphalen C, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller CA, Kahl C, Seipelt G, Kullmann F, Heinrich K, Holch JW, Alig A, Jung A, Modest DP, Heinemann V
doi: 10.1016/j.ejca.2025.115399
Lung, Respiratory and Thoracic Cancer
Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study
Lung Cancer
Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L
doi: 10.1016/j.lungcan.2025.108436
RECOMMENDED
Breast Cancer
Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer
★ 1
Recommended by
Dr Andreas Müller, Faculty Member
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Eur J Cancer
Hanvic B, Joureau-Chabert A, Ouldbey Y, Toussaint P, Chanel E, Blanc E, Heudel P, Montagnier V, Pérol D, Bachelot T
doi: 10.1016/j.ejca.2025.115791
CHICAGO 2025
Lung, Respiratory and Thoracic Cancer
IMforte: Adding lurbinectedin to atezolizumab improves PFS and OS as first-line maintenance therapy in patients with ES-SCLC
Genitourinary Cancer
First-Line Therapy For Advanced Non-Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
JAMA Oncol
Petrelli F, Verri E, Ghidini A, Vavassori I, Lonati V, Nolè F, Dottorini L
doi: 10.1001/jamaoncol.2025.1891
Genitourinary Cancer
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Clin Cancer Res
Bidkar AP, Peter R, Wadhwa A, Bobba KN, Bidlingmaier S, Meher N, Chou J, Greenland N, Dasari C, Naik S, Raveendran A, Basak M, Camara Serrano JA, Steri V, Kogan S, Oskowitz A, He J, Wilson DM, Aggarwal R, Sriram R, VanBrocklin HF, Seo Y, Liu B, Flavell RR
doi: 10.1158/1078-0432.CCR-24-2850
Further Publications
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)
Eur J Cancer
Maglietta G, Damato A, Finotto S, Mandarà M, Tamberi S, Grisanti S, Brighenti M, Tiseo M, Montesarchio V, Catino A, Gelsomino F, Giovanardi F, Antonuzzo L, Romagnani A, Gervasi E, Di Maio M, Pinto C
doi: 10.1016/j.ejca.2025.115296